Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro
- PMID: 17310826
Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro
Abstract
Although HIV protease inhibitor (PI) drugs predominantly target HIV proteases 1 and 2, it is also known that part of their efficacy is due to selective inhibition of the proteasome. The pathogenicity of high-risk human papilloma virus (HPV) is dependent on expression of viral E6 proteins which inappropriately activate the 26S proteasome to degrade p53 and other cellular proteins that are detrimental to viral replication. Comparison of the ability of the PIs indinavir, ritonavir, amprenavir, lopinavir, atazanavir, nelfinavir and saquinavir to inhibit E6-mediated proteasomal degradation of mutant p53 in E6-transfected C33A cells showed that 15 microM lopinavir, 1 mM indinavir or 125 microM ritonavir treatment for 24 h produced a stable increase in the level of nuclear p53 in these cells with minimal cell death. After 4 h exposure of HPV16+ve SiHa cells to 15 microM lopinavir, a transient increase in wild-type p53 expression was observed associated with a 7% reduction in the chymotryptic activity of the 205 proteasome and apoptosis after 24h. Comparison of growth rates of PI treated SiHa, CaSki, C33A, C33A-E6 and non-transformed NIH/3T3 cells showed that SiHa were the most sensitive, whereas NIH/3T3 were least affected. In conclusion, these data show that specific HIV PIs such as lopinavir and possibly indinavir, can induce selective toxicity of HPV-transformed cervical carcinoma cells expressing wild-type p53 and may form the basis of a topically applied alternative to surgery for the treatment of HPV-related premalignant lesions of the cervix.
Similar articles
-
RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53.Apoptosis. 2008 Feb;13(2):273-81. doi: 10.1007/s10495-007-0163-8. Apoptosis. 2008. PMID: 18060502
-
Raman chemical mapping reveals site of action of HIV protease inhibitors in HPV16 E6 expressing cervical carcinoma cells.Anal Bioanal Chem. 2010 Dec;398(7-8):3051-61. doi: 10.1007/s00216-010-4283-6. Epub 2010 Oct 19. Anal Bioanal Chem. 2010. PMID: 20957472
-
Recombinant adenovirus-p53 gene transfer and cell-specific growth suppression of human cervical cancer cells in vitro and in vivo.Gynecol Oncol. 2004 Feb;92(2):611-21. doi: 10.1016/j.ygyno.2003.10.033. Gynecol Oncol. 2004. PMID: 14766255
-
The role of the E6-p53 interaction in the molecular pathogenesis of HPV.Oncogene. 1999 Dec 13;18(53):7690-700. doi: 10.1038/sj.onc.1202953. Oncogene. 1999. PMID: 10618709 Review.
-
The role of TP53 in Cervical carcinogenesis.Hum Mutat. 2003 Mar;21(3):307-12. doi: 10.1002/humu.10178. Hum Mutat. 2003. PMID: 12619117 Review.
Cited by
-
Topical therapies for the treatment of cervical intraepithelial neoplasia (CIN) 2-3: A narrative review.Gynecol Oncol Rep. 2020 Jul 2;33:100608. doi: 10.1016/j.gore.2020.100608. eCollection 2020 Aug. Gynecol Oncol Rep. 2020. PMID: 32685652 Free PMC article. Review.
-
Susceptibility of HPV-18 Cancer Cells to HIV Protease Inhibitors.Viruses. 2024 Oct 17;16(10):1622. doi: 10.3390/v16101622. Viruses. 2024. PMID: 39459955 Free PMC article.
-
The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines.Oncol Lett. 2016 Oct;12(4):2493-2500. doi: 10.3892/ol.2016.5008. Epub 2016 Aug 16. Oncol Lett. 2016. PMID: 27698818 Free PMC article.
-
Proteasome activation by hepatitis C core protein is reversed by ethanol-induced oxidative stress.Gastroenterology. 2008 Jun;134(7):2144-52. doi: 10.1053/j.gastro.2008.02.063. Epub 2008 Mar 4. Gastroenterology. 2008. PMID: 18549882 Free PMC article.
-
A Single-Arm, Proof-Of-Concept Trial of Lopimune (Lopinavir/Ritonavir) as a Treatment for HPV-Related Pre-Invasive Cervical Disease.PLoS One. 2016 Jan 29;11(1):e0147917. doi: 10.1371/journal.pone.0147917. eCollection 2016. PLoS One. 2016. PMID: 26824902 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous